Dr. Ravandi on Targeting CD33 in Relapsed/Refractory AML

Video

In Partnership With:

Farhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses targeting CD33 in patients with relapsed/refractory acute myeloid leukemia.

Farhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses targeting CD33 in patients with relapsed/refractory acute myeloid leukemia (AML).

Considering recent FDA approvals, patients with relapsed/refractory AML still have limited treatment options, Ravandi says. CD33 is expressed by virtually all patients with AML, making it a somewhat universal target. Bispecific antibodies have shown impact in relapsed/refractory acute lymphocytic leukemia, giving investigators the idea that this class of agents may work in AML as well.

Findings from a phase I study of the anti-CD33 bispecific T-cell engager antibody construct AMG 330 were presented at the 2018 ASH Annual Meeting. Patients enrolled on this trial had relapsed/refractory AML with >5% blasts in their bone marrow. Responses were observed in 5 out of 40 patients. These responses consisted of 2 complete responses (CRs), 2 CRs with incomplete count recovery, and 1 morphologic leukemia-free state.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD